ReviewCells2026
Molecular Dynamics of PPAR Nuclear Receptors: From Ligand Binding to Transcriptional Regulation.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peroxisome proliferator-activated receptors (PPARα, PPARβ/δ, and PPARγ) are ligand-regulated nuclear receptors that coordinate lipid metabolism, glucose homeostasis, inflammation, adipogenesis, differentiation, and disease-associated transcriptional programs. Although early structural models emphasized ligand-dependent stabilization of helix 12 (H12) and the activation function-2 surface (AF-2), evidence from molecular dynamics (MD) simulations, NMR, HDX-MS, crystallography, mutagenesis, and biochemical assays supports a more complex conformational-ensemble mechanism. Apo and ligand-bound PPARs populate multiple functional substates whose distributions are shifted by ligands, RXR heterodimerization, DNA binding, co-regulators, post-translational modifications, and disease-associated mutations. This review summarizes MD and integrative structural studies of PPAR conformational dynamics, isoform-specific behavior, PPAR-RXR and co-regulator interactions, ligand entry, graded activation, inverse agonism, disease-associated mutations, and phosphorylation-dependent regulation. PPARγ is the most extensively characterized isoform, whereas PPARα and particularly PPARβ/δ remain comparatively underexplored by atomistic and enhanced-sampling approaches. MD is most informative when it extends beyond post-docking pose stability and is integrated with long-timescale sampling, free-energy methods, dynamic-network analysis, and experimental validation. Future simulations should increasingly model biologically realistic assemblies containing RXR, DNA, coactivators or corepressors, disease mutations, and post-translational modifications to connect ligand chemistry with receptor allostery, transcriptional output, and disease biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.